{
  "id": 20739307,
  "title": "Sellas’ cancer vaccine extends survival in blood cancer trial, company says",
  "url": "https://urgent.news/2026/11/19/sellas-cancer-vaccine-extends-survival-in-blood-cancer-trial-company",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-19T11:05:54.000Z",
  "source": {
    "name": "The Hindu Health",
    "slug": "the-hindu-health",
    "url": "https://www.thehindu.com/sci-tech/health/sellas-cancer-vaccine-extends-survival-in-blood-cancer-trial-company-says/article71719791.ece"
  },
  "original_language": "en",
  "account": "Sellas Life Sciences announced on November 17, 2026 that its experimental cancer vaccine, galinpepimut-S or GPS, extended the survival of patients with acute myeloid leukemia in a late-stage clinical trial. The vaccine, which targets a fast-growing form of blood cancer, resulted in median survival of 24 months for patients who received it, compared to 14.7 months for those who received standard treatment. Sellas plans to request approval from the U.S. Food and Drug Administration for the vaccine. The company's shares were halted during premarket trading.",
  "summary": "The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukaemia, a fast-growing cancer of the blood and bone marrow",
  "key_points": [
    "Sellas Life Sciences' vaccine GPS extended survival in AML trial.",
    "Median survival increased to 24 months with GPS vs 14.7 months standard treatment.",
    "Company plans to seek FDA approval for the cancer vaccine."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}